Stimulation by octanoate of insulin release from isolated rat pancreas

Using pieces of rat pancreas incubated in Krebs-bicarbonate buffer containing 0.6 mg. glucose/ml., it has been found that addition of 3.0 mM. octanoate to the incubation medium significantly (p < .001) increased insulin release above control levels by 4.94 +/- 0.89 [mu]U. insulin/mg. of pancreatic tissue. Increasing the glucose concentration in the incubation medium to 3.0 mg./ml. without addition of octanoate produced a slightly smaller though significant (p < .05) increase in insulin release (2.96 +/- 0.96 [mu]U./mg.) above control levels. In conclusion, octanoate is capable of directly stimulating additional release of insulin by the beta-cells of the pancreas.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/33336/1/0000733.pd

IN-VIVO AND IN-VITRO EFFECTS OF POLYVINYLPYRROLIDONE ON PLATELET ADHESIVENESS IN HUMAN BLOOD

Intravenous infusion of 500 ml. 6% polyvinylpyrrolidone (P.V.P. (Mw 40,000) in isotonic saline solution over a 2-hour period significantly diminished platelet adhesiveness in eight subjects from 27% before infusion to as low as 10% at the end of the infusion. 5 hours after the end of the infusion, platelet adhesiveness was still significantly reduced (16%). The addition of P.V.P. to citrated blood in vitro significantly decreased platelet adhesiveness. Both in vivo and in vitro, the platelet-count was not significantly altered by P.V.P. The in-vivo change in platelet adhesiveness is similar to that reported by others with dextran-a plasma expander that differs chemically from P.V.P.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/33274/1/0000666.pd

Clinical observations on a new antihypertensive drug, 2-(2,6-dichlorphenylamine)-2-imidazoline hydrochloride

The drug 2-(2,6-dichlorphenylamine)-2-imidazoline hydrochloride, available as Catapres, was given to 16 patients with established hypertension. Six patients were studied for one month to detect abnormalities in carbohydrate metabolism. None were found. Ten severely hypertensive patients were maintained for from 5 to 11 months on Catapres and diuretics.In a single dose, Catapres invariably lowered the blood pressure significantly, but without producing orthostatic hypotension. The maximum effect occurred between 2 and 3 hours after ingestion of the drug. The duration of drug action was 4 to 6 hours.In long-term treatment of ten patients, Catapres, combined with a diuretic, proved to be as effective as a diuretic plus guanethidine or Aldomet, which the patients had previously been taking. A dose of 0.400 to 1.200 mg. of Catapres was equivalent to 1.5 to 2.0 Gm. of Aldomet or 50 to 100 mg. of guanethidine.The chief side effect of the drug was drowsiness, but this was not incapacitating, it did not require cessation of treatment, and it became less prominent with the passage of time. In patients who had experienced severe orthostatic hypotension on other drug regimens, the condition was considerably relieved by Catapres. No signs of toxicity were noted, as judged by carbohydrate tolerance, BUN, SGPT, alkaline phosphatase, and hematologic determinations.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/32994/1/0000378.pd

The medical malpractice survival handbook: American college of legal medicine

xv+531hlm.;23c